BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 17671693)

  • 1. Downregulation of retinoblastoma protein is involved in the enhanced cytotoxicity of 4-hydroxytamoxifen plus mifepristone combination therapy versus antiestrogen monotherapy of human breast cancer.
    Schoenlein PV; Hou M; Samaddar JS; Gaddy VT; Thangaraju M; Lewis J; Johnson M; Ganapathy V; Kallab A; Barrett JT
    Int J Oncol; 2007 Sep; 31(3):643-55. PubMed ID: 17671693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mifepristone induces growth arrest, caspase activation, and apoptosis of estrogen receptor-expressing, antiestrogen-resistant breast cancer cells.
    Gaddy VT; Barrett JT; Delk JN; Kallab AM; Porter AG; Schoenlein PV
    Clin Cancer Res; 2004 Aug; 10(15):5215-25. PubMed ID: 15297425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of antiproliferation and apoptosis in estrogen receptor negative MDA-231 human breast cancer cells by mifepristone and 4-hydroxytamoxifen combination therapy: a role for TGFbeta1.
    Liang Y; Hou M; Kallab AM; Barrett JT; El Etreby F; Schoenlein PV
    Int J Oncol; 2003 Aug; 23(2):369-80. PubMed ID: 12851686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin-like growth factor 1 attenuates antiestrogen- and antiprogestin-induced apoptosis in ER+ breast cancer cells by MEK1 regulation of the BH3-only pro-apoptotic protein Bim.
    Periyasamy-Thandavan S; Takhar S; Singer A; Dohn MR; Jackson WH; Welborn AE; LeRoith D; Marrero M; Thangaraju M; Huang S; Schoenlein PV
    Breast Cancer Res; 2012 Mar; 14(2):R52. PubMed ID: 22429491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indole-3-carbinol and tamoxifen cooperate to arrest the cell cycle of MCF-7 human breast cancer cells.
    Cover CM; Hsieh SJ; Cram EJ; Hong C; Riby JE; Bjeldanes LF; Firestone GL
    Cancer Res; 1999 Mar; 59(6):1244-51. PubMed ID: 10096555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Partial antagonism between steroidal and nonsteroidal antiestrogens in human breast cancer cell lines.
    Müller V; Jensen EV; Knabbe C
    Cancer Res; 1998 Jan; 58(2):263-7. PubMed ID: 9443403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Steroid receptor-mediated cytotoxicity of an antiestrogen and an antiprogestin in breast cancer cells.
    Bardon S; Vignon F; Montcourrier P; Rochefort H
    Cancer Res; 1987 Mar; 47(5):1441-8. PubMed ID: 3815345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Additive effect of mifepristone and tamoxifen on apoptotic pathways in MCF-7 human breast cancer cells.
    El Etreby MF; Liang Y; Wrenn RW; Schoenlein PV
    Breast Cancer Res Treat; 1998 Sep; 51(2):149-68. PubMed ID: 9879777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
    Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
    Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 4-Hydroxytamoxifen inhibits proliferation of multiple myeloma cells in vitro through down-regulation of c-Myc, up-regulation of p27Kip1, and modulation of Bcl-2 family members.
    Gauduchon J; Gouilleux F; Maillard S; Marsaud V; Renoir JM; Sola B
    Clin Cancer Res; 2005 Mar; 11(6):2345-54. PubMed ID: 15788686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells.
    Aesoy R; Sanchez BC; Norum JH; Lewensohn R; Viktorsson K; Linderholm B
    Mol Cancer Res; 2008 Oct; 6(10):1630-8. PubMed ID: 18922978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of histone deacetylase enhances the anti-proliferative action of antiestrogens on breast cancer cells and blocks tamoxifen-induced proliferation of uterine cells.
    Hodges-Gallagher L; Valentine CD; Bader SE; Kushner PJ
    Breast Cancer Res Treat; 2007 Nov; 105(3):297-309. PubMed ID: 17186358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. c-Jun activation is required for 4-hydroxytamoxifen-induced cell death in breast cancer cells.
    Madeo A; Vinciguerra M; Lappano R; Galgani M; Gasperi-Campani A; Maggiolini M; Musti AM
    Oncogene; 2010 Feb; 29(7):978-91. PubMed ID: 19935718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant percutaneous 4-hydroxytamoxifen decreases breast tumoral cell proliferation: a prospective controlled randomized study comparing three doses of 4-hydroxytamoxifen gel to oral tamoxifen.
    Rouanet P; Linares-Cruz G; Dravet F; Poujol S; Gourgou S; Simony-Lafontaine J; Grenier J; Kramar A; Girault J; Le Nestour E; Maudelonde T
    J Clin Oncol; 2005 May; 23(13):2980-7. PubMed ID: 15860853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein Kinase C alpha is a marker for antiestrogen resistance and is involved in the growth of tamoxifen resistant human breast cancer cells.
    Frankel LB; Lykkesfeldt AE; Hansen JB; Stenvang J
    Breast Cancer Res Treat; 2007 Aug; 104(2):165-79. PubMed ID: 17061041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor and anticancer stem cell activities of eribulin mesylate and antiestrogens in breast cancer cells.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Moriya T
    Breast Cancer; 2016 May; 23(3):425-36. PubMed ID: 25552385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of tumor suppressor proteins, p53 and retinoblastoma, by estrogen and antiestrogens in breast cancer cells.
    Hurd C; Khattree N; Dinda S; Alban P; Moudgil VK
    Oncogene; 1997 Aug; 15(8):991-5. PubMed ID: 9285694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation.
    Jeng MH; Parker CJ; Jordan VC
    Cancer Res; 1992 Dec; 52(23):6539-46. PubMed ID: 1423300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytostatic and cytotoxic action of Z-1, 1-dichloro-2,3-diphenylcyclopropane in three human breast cancer cell lines.
    ter Haar E; Day BW
    Anticancer Res; 1996; 16(3A):1107-15. PubMed ID: 8702221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival.
    Menendez JA; Oza BP; Colomer R; Lupu R
    Int J Oncol; 2005 Jun; 26(6):1507-15. PubMed ID: 15870863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.